Lifecome Biochemistry Co Ltd - Asset Resilience Ratio
Lifecome Biochemistry Co Ltd (002868) has an Asset Resilience Ratio of 4.69% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 002868 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2019)
This chart shows how Lifecome Biochemistry Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 002868 asset base.
Liquid Assets Composition Over Time
This chart breaks down Lifecome Biochemistry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Lifecome Biochemistry Co Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥45.35 Million | 4.69% |
| Total Liquid Assets | CN¥45.35 Million | 4.69% |
Asset Resilience Insights
- Limited Liquidity: Lifecome Biochemistry Co Ltd maintains only 4.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecome Biochemistry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lifecome Biochemistry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for Lifecome Biochemistry Co Ltd (2019–2019)
The table below shows the annual Asset Resilience Ratio data for Lifecome Biochemistry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 17.13% | CN¥173.03 Million ≈ $25.32 Million |
CN¥1.01 Billion ≈ $147.80 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.